Who is sponsoring NCT02147951?

NCT02147951 is sponsored by Amgen.

What drugs are being tested in NCT02147951?

Interventions in NCT02147951: Talimogene Laherparepvec.

What condition does NCT02147951 study?

NCT02147951 studies Unresected Stage IIIb to IVM1c Melanoma.

Is NCT02147951 still recruiting?

NCT02147951 is currently no longer available. Last updated 1 March 2016.

Last reviewed 2016-03-01 · How we verify

NCT02147951

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

NO LONGER AVAILABLE Last updated 1 March 2016

What this trial tests

trial testing Talimogene Laherparepvec in Unresected Stage IIIb to IVM1c Melanoma. No longer available.

Quick facts

Lead sponsor	Amgen
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	24 locations across United States

Drugs / interventions tested

Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) — full drug profile →

Conditions studied

Unresected Stage IIIb to IVM1c Melanoma — all drugs for Unresected Stage IIIb to IVM1c Melanoma →

Sponsor

Amgen — full company profile →

Who can join

Adults 18 to 95, any sex, with Unresected Stage IIIb to IVM1c Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Expanded access of Talimogene Laherparepvec for subjects with unresected, stage IIIb to IVM1c Melanoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Trial Watch-Oncolytic viruses and cancer therapy.
Pol J, Buqué A, Aranda F, Bloy N, et al · · 2016 · cited 87× · PMID 27057469 · DOI 10.1080/2162402x.2015.1117740
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
Hamid O, Hoffner B, Gasal E, Hong J, et al · · 2017 · cited 59× · PMID 28712033 · DOI 10.1007/s00262-017-2025-8
Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
Chesney J, Imbert-Fernandez Y, Telang S, Baum M, et al · · 2018 · cited 13× · PMID 29561296 · DOI 10.1097/cmr.0000000000000444

Verify or expand the search:

Other trials of Talimogene Laherparepvec

Trials testing the same drug.

NCT06660810 — Neoadjuvant Intralesional Injection of Talimogene Laherparepvec · Phase 2 · active not recruiting
NCT04599062 — TVEC and Preop Radiation for Sarcoma (8 ml Dose) · Phase 1, PHASE2 · active not recruiting
NCT03554044 — T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer · Phase 1 · completed
NCT04163952 — Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of · Phase 1 · terminated
NCT02923778 — Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be · Phase 2 · active not recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02147951 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 1 March 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02147951.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing